Esk

Chennai

[Esk @esenthil84]

@sumanthraman @TVKVijayHQ Let's start with online publication of biometric attendance of govt staff on daily or monthly basis. This simple move will ensure everyone come on time. This will reduce congestion in govt offices and improve monitoring .

[Oncology Brothers @OncBrothers]

Why is RASolute-302 being celebrated? Because historically, we have had limited options for pancreatic cancer. We definitely need to do better but RAS is now finally actionable!!! Previous data in this space….

#pancsm #gism #OncTwitter #MedTwitter #daraxonrasib

[Vincent Rajkumar @VincentRK]

Here is the story for those interested in the preclinical discovery of Daraxonrasib. #ASCO26
It’s talent and hard work.
@marklewismd @Rfonsi1

https://t.co/hMnGEJL0Vn

[Paolo Tarantino @PTarantinoMD]

Highly impactful update from SERENA6. Very nice plateau in the PFS curves with longer follow up, and dramatic reduction in ctDNA and improvement in QoL which suggests deep benefit. Harder to interpret PFS2. Hoping to have this option available for our patients soon. #ASCO26

[Moffitt Cancer Center @MoffittNews]

Live from #ASCO26: Abdul Naqash, MD (@thenasheffect @StephensonCC), reviews the year's biggest advances in lung cancer and how they're shaping clinical practice.

DeLLphi-304
• Tarlatamab in the 2nd line is raising the survival bar for patients and rewriting the CNS narrative in SCLC with brain metastasis.

LIBRETTO-432:
• Right target, right therapy, right time.
• Adjuvant selpercatinib provides an EFS benefit in RET fusion-positive early-stage NSCLC.

EA-5142:
• Negative DFS benefit of adjuvant nivolumab in EA5142 questions the universal notion of adjuvant ICI in early-stage NSCLC.

• New findings from #ASCO26 suggest the timing and role of immunotherapy in resectable early-stage NSCLC remain areas of active study.

#MoffittASCO26

[Tuğba Başoğlu, MD @tugbawitter]

#ASCO2026

HER2CLIMB-05 delivers across every key subgroup.

Adding tucatinib to maintenance trastuzumab/pertuzumab significantly prolonged PFS in HER2+ metastatic breast cancer:

🧠 Brain metastases: 8.5 vs 4.2 months
🌸 HR+ disease: 25.0 vs 18.1 months
🚀 De novo metastatic disease: 28.9 vs 16.8 months

Consistent benefit across subgroups reinforces tucatinib as a compelling maintenance strategy after first-line THP.@OncBrothers @OncoAlert @Larvol

[Gaia Griguolo @GaiaGriguolo]

🚨🚨For Monday morning:
Denosumab q12w vs q4w has non inferior efficacy in preventing symptomatic skeletal events and reduces toxicities and costs in PTS with mBC or mCRPC and bone metastases

Sometimes less is more!
A plause to the SAKK investigators!

@OncoAlert #asco26

[Eric Topol @EricTopol]

Another major advance vs cancer! @ASCO #ASCO26
Personalized neoantigen mRNA vaccine 5 year follow-up vs metastatic melanoma reduced recurrence and death by 49% (on top of Keytruda)
https://t.co/NadITTYIT2

[Eric K. Singhi, MD @lungoncdoc]

7yr CROWN update of 1L lorlatinib

55% progression-free at 7 YEARS.
Median PFS STILL not reached.

In metastatic solid tumors, this is essentially unheard of. Let that sink in.

And hopefully, one day, this becomes the standard (or even better) for ALL metastatic cancers.#ASCO26

[Erman Akkus @Erman_Akkus]

Metastatic breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up† - Annals of Oncology @myESMO @OncoAlert #guideline #cancer #oncology #breast #ASCO26 https://t.co/0y7QbqJQjo

[Esk @esenthil84]

@aravind @theliverdrALT

[Esk @esenthil84]

@NelsonMogaka_ CVS -S1 S2+
RS -- NVBS , B/L AE +

[Yu Jing @ChinaSpox_India]

Indian urologist Dr. Syed Mohammed Ghouse, stationed in #Wuhan 🇨🇳, successfully performed a robot-assisted ureteral reimplantation in just 90 minutes on a patient 3,000 km away in Hyderabad, India—thanks to China-developed robotics and 5G technology. 🇨🇳🤝🇮🇳

Life-saving care, transcending borders. 🌏❤️

Read more: https://t.co/STaWiD9WKp

[Esk @esenthil84]

@karthik2k2 When Raga was talking about United States ( America ) -- he translated as united states of India. Not simple translation errors. He had no clue as to what Raga was even talking about. Tn Congress deserves a good leader

[Global Society of Rare Genitourinary Tumors @GTumors]

🚨 Major update in penile cancer care 🚨

The 2026 EAU–ASCO guidelines emphasize:

🔬 Refined risk stratification (pathologic + molecular)
🧠 Routine US ± FNA for nodal staging
🧬 Selective genomic testing
🔪 Expanded role of organ-sparing surgery
🏥 Centralization of care improves outcomes

⚠️ Still: much of the evidence remains retrospective → need for high-quality trials in rare GU malignancies

A step forward toward more personalized, patient-centered care.

@SpiessPhilippe @drgaganprakash @LuisMedinaMD @npaesa @CMercinelli @dramandeeparora @MoffittNews @TataMemorial @AmerUrological @UroOnc @SUO_YUO @CAU_URO @orchidcancer @ERN_eUROGEN @EauPatient @JadChahoud @BrouwerOscar @BryanRumble @MaartenAlbersen @DrScottTagawa @CurtisPettaway1 @AyresBenjamin

[Rohit Malde @roxboxfix]

Vepdegestrant in ER+, HER2–, ESR1-Mutated Breast Cancer
US FDA approval

VERITAC-2 Trial : An overview

Era of niche precision endocrine therapy has just begun

[Rohit Malde @roxboxfix]

2nd Line Treatment Options in Mets Breast Cancer

Post Progression after AI + Cdk 4/6 inhibitors use in 1st Line

Mandatory = Organise NGS testing

See the Wonderful options

Trial evidence and Efficacy snd Salient Toxicity

[Rohit Malde @roxboxfix]

Ros-1 Mets NSCLC : Approved Therapies and Comparison of CNS activity
An overview at a glance of Trials
Where we have reached so far

[CA: A Cancer Journal for Clinicians @CACancerJournal]

This recent review describes new advances in fertility preservation & cancer, including novel treatments in male and female fertility. Additionally, the authors call for more inclusive methods for gender minorities.

https://t.co/uIq7xsWfMX

@BrookeCherven @lghazal @OncoAlert

[Rohit Malde @roxboxfix]

2nd Line Treatment Options for Advanced Cholangiocarcinomas

Focus on FGFR inhibitors